Naptumomab estafenatox: a new immunoconjugate

Bibliography

• Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002;2:750-63
   PubMed Web of Science ®Google Scholar
• Dohlsten M, Hansson J, Ohlsson L, Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo. Proc Natl Acad Sci 1995;92:9791-5
   PubMed Web of Science ®Google Scholar
• Dohlsten M, Abrahmsen L, Bjork P, Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy. Proc Natl Acad Sci USA 1994;91:8945-9
   PubMed Web of Science ®Google Scholar
• Rosendahl A, Hansson J, Sundstedt A, Immune response during tumor therapy with antibody-superantigen fusion proteins. Int J Cancer 1996; 68:109-13
   PubMed Web of Science ®Google Scholar
• Litton MJ, Dohlsten M, Hansson J, Tumor therapy with an antibody-targeted superantigen generates a dichotomy between local and systemic immune responses. Am J Pathol 1997;150:1607-18
   PubMed Web of Science ®Google Scholar
• Hole N, Stern PL. Isolation and characterization of 5T4, A tumor-associated antigen. Int J Cancer 1990;45:179-84
   PubMed Web of Science ®Google Scholar
• Hole N, Stern PL. A 72kD trophoblast glycoprotein defined by a monoclonal antibody. Br J Cancer 1988;57:239-46
   PubMed Web of Science ®Google Scholar
• Kobe B, Deisenhofer J. The leucine-rich repeat: a versatile binding motif. Trends Biochem Science 1994;19:415-21
   PubMed Web of Science ®Google Scholar
• Carsberg CJ, Myers KA, Stern PL. Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells. Int J Cancer 1996;68:84-92
   PubMed Web of Science ®Google Scholar
• Southall PJ, Boxer GM, Bagshawe KD, Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer 1990;61(1):89-95
   PubMed Web of Science ®Google Scholar
• Forsberg G, Ohlsson L, Brodin T, Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen. Br J Cancer 2001;85(1):129-36
   PubMed Web of Science ®Google Scholar
• Griffiths RW, Gilham DE, Dangoor A, Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br J Cancer 2005;93:670-7
   PubMed Web of Science ®Google Scholar
• Starzynska T, Rahi V, Stern PL. The expression of 5T4 antigen in colorectal and gastric carcinoma. Br J Cancer 1992;66:867-9
   PubMed Web of Science ®Google Scholar
• Brooks M. Breast cancer screening and biomarkers. Methods Mol Biol 2009;472:307-21
   PubMedGoogle Scholar
• Sievers EL, Appelbaum FR, Spielberger RT, Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999;93:3678-84
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Wang QC, FitzGerald DJ, Pastan I. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. Int J Cancer 1999;81:148-55
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Squires DR, Stetler-Stevenson M, Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005;23:6719-29
   PubMed Web of Science ®Google Scholar
• Mirick GR, Bradt BM, DeNardo SJ, DeNardo DG. A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) response to monoclonal antibodies. Not four letter words. Q J Nucl Med Mol Imaging 2004;48:251-7
   PubMed Web of Science ®Google Scholar
• Kricka LJ, Schmerfeld-Pruss D, Kaladas P, Survey of methods for measuring human anti-mouse antibodies. HAMA Survey Group. Clin Chim Acta 1993;215:153-63
   PubMed Web of Science ®Google Scholar
• Shaw DM, Connolly NB, Patel PM, A phase II study of 5T4 oncofetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer 2007;96:567-74
   PubMed Web of Science ®Google Scholar
• Borghaei H, Alpaugh K, Hedlund G, Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small cell lung cancer. J Clin Oncol 2009;27:4116-23
   PubMed Web of Science ®Google Scholar
• Dermime S, Gilham DE, Shaw DM, Vaccine and antibody-directed T cell tumour immunotherapy. Biochim Biophys Acta 2004;1704:11-35
   PubMed Web of Science ®Google Scholar
• Petersson K, Forsberg G, Walse B. Interplay between superantigens and immunoreceptors. Scand J Immunol 2004;59:345-55
   PubMed Web of Science ®Google Scholar
• Dohlsten M, Kalland T, Gunnarsson P, Man-made superantigens: tumor-selective agents for T-cell-based therapy. Adv Drug Deliv Rev 1998;31:131-42
   Google Scholar
• Alpaugh RK, Schultz J, McAleer C, Superantigen-targeted therapy: phase I escalating repeat dose trial of the fusion protein PNU-214565 in patients with advanced gastrointestinal malignancies. Clin Cancer Res 1998;4:1903-14
   PubMed Web of Science ®Google Scholar
• Cheng JD, Babb JS, Langer C, Individualized patient dosing in phase I clinical trials: The role of escalation with overdose control in PNU-214936. J Clin Oncol 2004;22:602-9
   PubMed Web of Science ®Google Scholar
• Alpaugh RK, Weiner LM, Persson B, Nacolomab Tafenatox. Drugs Future 1997;22(11):1226-30
   Google Scholar
• Erlandsson E, Andersson K, Cavallin A, Identification of the antigenic epitopes in staphylococcal enterotoxins A and E and design of a superantigen for human cancer therapy. J Mol Biol 2003;333:893-905
   PubMed Web of Science ®Google Scholar
• Babb J, Rogatko A, Zacks S. Cancer Phase I clinical trials: efficient dose escalation with overdose control. Stat Med 1998;17:1103-20
   PubMed Web of Science ®Google Scholar
• Sundstedt A, Celander M, Ohman MW, Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects. Int Immunopharmacol 2009;9:1063-70
   PubMed Web of Science ®Google Scholar
• Rosendahl A, Kristensson K, Hansson J, Repeated treatment with antibody-targeted superantigens strongly inhibits tumor growth. Int J Cancer 1998;76:274-83
   PubMed Web of Science ®Google Scholar